These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21133885)

  • 21. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Beaussant Y; Daguindau E; Pugin A; Mohty M; Avet-Loiseau H; Roos-Weil D; Michallet M; Chevalier P; Raus N; El-Cheikh J; Tabrizi R; Huyn A; Buzyn A; Socié G; Vincent L; Guilhot F; Yakoub-Agha I; Lenain P; François S; Beckerich F; Lioure B; Bulabois CE; Deconinck E;
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1452-9. PubMed ID: 25911579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment.
    Daguindau E; Lioure B; Buzyn A; Robin M; Faucher C; Kuentz M; Tiberghien P; Deconinck E
    Bone Marrow Transplant; 2010 Jan; 45(1):177-80. PubMed ID: 19430502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Fabre C; Koscielny S; Mohty M; Fegueux N; Blaise D; Maillard N; Tabrizi R; Michallet M; Socié G; Yakoub-Agha I; Garban F; Uzunov M; François S; Contentin N; Lapusan S; Bourhis JH
    Haematologica; 2012 Apr; 97(4):482-90. PubMed ID: 22058218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
    Villar S; Chevret S; Poire X; Joris M; Chevallier P; Bourhis JH; Forcade E; Chantepie S; Beauvais D; Raus N; Bay JO; Loschi M; Devillier R; Duléry R; Ceballos P; Rubio MT; Servais S; Nguyen S; Robin M
    Bone Marrow Transplant; 2024 Jul; 59(7):965-973. PubMed ID: 38514813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
    Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
    Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers.
    Cordonnier C; Ribaud P; Herbrecht R; Milpied N; Valteau-Couanet D; Morgan C; Wade A;
    Clin Infect Dis; 2006 Apr; 42(7):955-63. PubMed ID: 16511759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis.
    Ruggeri A; Rocha V; Masson E; Labopin M; Cunha R; Absi L; Boudifa A; Coeffic B; Devys A; De Matteis M; Dubois V; Hanau D; Hau F; Jollet I; Masson D; Pedron B; Perrier P; Picard C; Ramouneau-Pigot A; Volt F; Charron D; Gluckman E; Loiseau P
    Haematologica; 2013 Jul; 98(7):1154-60. PubMed ID: 23242594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
    Jourdan E; Maraninchi D; Reiffers J; Gluckman E; Rio B; Jouet JP; Michallet M; Molina L; Archimbaud E; Harousseau JL; Ifrah N; Attal M; Guilhot F; Kuentz M; Guyotat D; Pico JL; Dauriac C; Legros M; Dreyfus F; Bordigoni P; Leblond V; Gratecos N; Varet B; Auzanneau C; Blaise D
    Bone Marrow Transplant; 1997 May; 19(9):875-81. PubMed ID: 9156260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Barosi G; Bacigalupo A
    Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Duarte RF; Canals C; Onida F; Gabriel IH; Arranz R; Arcese W; Ferrant A; Kobbe G; Narni F; Deliliers GL; Olavarría E; Schmitz N; Sureda A
    J Clin Oncol; 2010 Oct; 28(29):4492-9. PubMed ID: 20697072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.